These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 15193677

  • 1. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.
    Sonntag S, Sundberg S, Lehtonen LA, Kleber FX.
    J Am Coll Cardiol; 2004 Jun 16; 43(12):2177-82. PubMed ID: 15193677
    [Abstract] [Full Text] [Related]

  • 2. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K, Klocke RC, Schipke JD, Gams E, Korbmacher B.
    Eur J Cardiothorac Surg; 2008 Aug 16; 34(2):326-31. PubMed ID: 18539040
    [Abstract] [Full Text] [Related]

  • 3. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction.
    De Luca L, Proietti P, Celotto A, Bucciarelli-Ducci C, Benedetti G, Di Roma A, Sardella G, Genuini I, Fedele F.
    Am Heart J; 2005 Sep 16; 150(3):563-8. PubMed ID: 16169341
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.
    Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K.
    Circulation; 2005 Mar 29; 111(12):1504-9. PubMed ID: 15781741
    [Abstract] [Full Text] [Related]

  • 8. Levosimendan improves postresuscitation outcomes in a rat model of CPR.
    Huang L, Weil MH, Sun S, Cammarata G, Cao L, Tang W.
    J Lab Clin Med; 2005 Nov 29; 146(5):256-61. PubMed ID: 16242524
    [Abstract] [Full Text] [Related]

  • 9. Effects of percutaneous transluminal septal myocardial ablation for obstructive hypertrophic cardiomyopathy on systolic and diastolic left ventricular function assessed by pressure-volume loops.
    Meliga E, Steendijk P, Valgimigli M, Ten Cate FJ, Serruys PW.
    Am J Cardiol; 2008 Apr 15; 101(8):1179-84. PubMed ID: 18394455
    [Abstract] [Full Text] [Related]

  • 10. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ.
    Anesth Analg; 2007 Apr 15; 104(4):766-73. PubMed ID: 17377079
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
    Stocker CF, Shekerdemian LS, Nørgaard MA, Brizard CP, Mynard JP, Horton SB, Penny DJ.
    Crit Care Med; 2007 Jan 15; 35(1):252-9. PubMed ID: 17133188
    [Abstract] [Full Text] [Related]

  • 12. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
    Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, Nikolaou M, Filippatos G, Kremastinos D.
    Am J Cardiol; 2006 Dec 01; 98(11):1489-92. PubMed ID: 17126656
    [Abstract] [Full Text] [Related]

  • 13. [Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty (PTCA) by intracoronary dipyridamole: hemodynamic, contractile and dynamic ventricular consequences].
    Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B.
    Z Kardiol; 1995 Nov 01; 84(11):898-910. PubMed ID: 8571641
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy.
    Guarracino F, Cariello C, Danella A, Doroni L, Lapolla F, Stefani M, Baldassarri R, Vullo C.
    Acta Anaesthesiol Scand; 2007 Oct 01; 51(9):1217-24. PubMed ID: 17850562
    [Abstract] [Full Text] [Related]

  • 16. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
    Pagel PS, Harkin CP, Hettrick DA, Warltier DC.
    J Pharmacol Exp Ther; 1995 Oct 01; 275(1):127-35. PubMed ID: 7562540
    [Abstract] [Full Text] [Related]

  • 17. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction.
    Missant C, Rex S, Segers P, Wouters PF.
    Crit Care Med; 2007 Mar 01; 35(3):707-15. PubMed ID: 17255859
    [Abstract] [Full Text] [Related]

  • 18. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.
    Lilleberg J, Sundberg S, Nieminen MS.
    J Cardiovasc Pharmacol; 1995 Mar 01; 26 Suppl 1():S63-9. PubMed ID: 8907133
    [Abstract] [Full Text] [Related]

  • 19. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure.
    Kerbaul F, Gariboldi V, Giorgi R, Mekkaoui C, Guieu R, Fesler P, Gouin F, Brimioulle S, Collart F.
    Crit Care Med; 2007 Aug 01; 35(8):1948-54. PubMed ID: 17568324
    [Abstract] [Full Text] [Related]

  • 20. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
    Kolseth SM, Nordhaug DO, Stenseth R, Sellevold O, Kirkeby-Garstad I, Wahba A.
    Eur J Cardiothorac Surg; 2009 Dec 01; 36(6):1024-30. PubMed ID: 19592266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.